NCT07059338View on ClinicalTrials.gov

Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
HER2 PositiveColorectal Cancer (CRC)
Interventions
DRUG

Trastuzumab +Cetuximab β+Irinotecan

Trastuzumab 4 mg/kg , Cetuximab β: 500 mg/m² ,Irinotecan 180 mg/m², repeat once every 2 weeks

Trial Locations (1)

Unknown

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT07059338 - Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter